Toric implantable collamer lens offers good results

Article

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results.

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results, according to Daniel Elies from the Instut Oftalmologic Integral, Barcelona, Spain.

The TICL was implanted into 63 eyes of 36 patients with myopic compound astigmatism. The mean preoperative spherical equivalent (SE) was -10.58±3.41 D and the mean preoperative astigmatism was -3.59±1.38 D. The standard recommendations from the manufacturer regarding preoperative measurements, nomogram and implantation technique were followed.

Following implantation of the TICL, mean SE was -10.26 D (p<0.0001) and mean cylinder was -2.87 D (p<0.0001). Holladay analysis of astigmatism showed a large reduction.

At one-year follow-up, 82.5% of eyes had SE within ±0.50 D and 68.3± had an uncorrected visual acuity (UCVA) equal to or better than the preoperative best corrected visual acuity (BCVA). Approximately 60% of eyes gained at least one line of best spectacle corrected visual acuity (BSCVA). At two weeks postoperatively, four eyes had an intraocular pressure (IOP) over 21 mmHg due to steroids. Two eyes (of the same patient) developed adenoviric KCT and five eyes showed tilted IOL, one of which required repositioning.

Overall, Dr Elies concluded that the TICL offers predictable and effective refractive results.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.